AP NEWS

2018 Respiratory Tract Infections Drug Development Pipeline Review - Tuberculosis, Diphtheria and Pertussis (Whooping Cough) - ResearchAndMarkets.com

August 17, 2018

DUBLIN--(BUSINESS WIRE)--Aug 17, 2018--The “Respiratory Tract Infections Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

Respiratory Tract Infections Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/h37blk/2018_respiratory?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180817005114/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Drug Discovery,Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/17/2018 05:58 AM/DISC: 08/17/2018 05:58 AM

http://www.businesswire.com/news/home/20180817005114/en

AP RADIO
Update hourly